Get notified when VTRS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Pfizer Opioid-Indemnity Dispute (new) — Pfizer requested payment under a provision requiring Viatris to pay 57% of opioid-related losses since July 2019; Viatris disputes the claim, with potential adverse impact if resolved against the company.
Viatris Q2 revenue +4.9% to $3.76B, but net loss widens 2483% on below-the-line costs
Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read
Key Changes
-
high
Net loss widened to -$118.8M (-$0.10/share) from -$4.6M prior year, while operating income fell 97% to $6.3M. The bottom-line deterioration did not come from operations—net income remained below operating income, indicating higher below-the-line deductions (taxes, interest, non-operating items), though the filing does not disclose the specific driver.
MD&A: Earnings Quality verify on EDGAR → -
high
Operating income collapsed 97% to $6.3M (from $233.0M) on $177.8M Tyrvaya® impairment, $86.8M Nashik fire charges, and $105.2M restructuring costs.
MD&A: Operating Income & Nashik verify on EDGAR → -
high
Total charges expected: $700-850M over three years. $105.2M recorded in H1 2026.
MD&A: 2026 Restructuring Program verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (COTY 10-K) is open in full — no account needed.
Partner
Trade VTRS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 26, 2026 · How we verify